<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00590226</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00048954</org_study_id>
    <secondary_id>791-2006</secondary_id>
    <nct_id>NCT00590226</nct_id>
  </id_info>
  <brief_title>Insulin Detemir Versus NPH Insulin In Hospitalized Patients With Diabetes</brief_title>
  <acronym>DEAN</acronym>
  <official_title>Comparative Trial Between Insulin Detemir Versus NPH Insulin In Hospitalized Patients With Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Emory University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Emory University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      High blood glucose levels in hospitalized patients with diabetes are associated with
      increased risk of medical complications. Improved glucose control with insulin injections may
      improve clinical outcome and prevent some of the hospital complications. It is not known;
      however, what is the best insulin regimen in hospitalized patients. Recently, the use of
      basal/bolus insulin therapy with detemir (Levemir®) and rapid-acting insulin (lispro, aspart,
      glulisine) has been shown to facilitate outpatient glycemic control with lower rate of
      hypoglycemic (low blood sugar) events in patients with diabetes. In this study, we will
      determine the efficacy and safety of the combination of detemir and aspart insulin in the
      inpatient management of subjects with diabetes. We hypothesize that in patients with type 2
      diabetes admitted to general medicine wards, treatment with insulin detemir once daily plus
      insulin aspart before meals will allow better glycemic control and lower rate of hypoglycemic
      events than treatment with twice a day NPH plus regular insulin before meals. Detemir is a
      long-acting insulin which is given subcutaneously (under the skin) once daily. Aspart is a
      rapid-acting insulin which is given subcutaneously several times a day and frequently before
      meals. Detemir and aspart insulins are approved for use in the treatment of patients with
      diabetes by the FDA.

      This investigator-initiated research will be conducted at Grady Memorial Hospital, Atlanta
      and at Rush University Medical Center, Chicago, IL. Dr. Umpierrez designed the study and will
      serve as principal investigator. A total of 65 patients will be recruited at Grady and 65
      patients at the Rush University Medical Center, Chicago, IL.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2006</start_date>
  <completion_date type="Actual">April 2008</completion_date>
  <primary_completion_date type="Actual">January 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean AM BG (mg/dl)</measure>
    <time_frame>during hospitalization</time_frame>
    <description>average AM daily BG with detemir insulin once daily plus insulin aspart before meals and NPH insulin twice daily plus regular insulin before meals in patients with DM2</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Hypoglycemic Events</measure>
    <time_frame>during hospitalization</time_frame>
    <description>number of patients with hypoglycemic events as defined as BG 40-59 mg/dl</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">130</enrollment>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>detremir + aspart insulin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Detemir insulin once daily + aspart insulin before meals three times a day at an initial total dose of 0.5 units/kg/day, subcutaneously</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NPH + regular insulin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>NPH insulin once a day + regular insulin before breakfast and dinner at an initial total dose of 0.5 units/kg/day, subcutaneously</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Detemir + aspart insulin before meals</intervention_name>
    <description>Detemir insulin SQ once daily + aspart insulin SQ before meals</description>
    <arm_group_label>detremir + aspart insulin</arm_group_label>
    <other_name>levemir</other_name>
    <other_name>novolog</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NPH insulin + regular insulin</intervention_name>
    <description>NPH insulin SQ + regular insulin SQ before breakfast and dinner</description>
    <arm_group_label>NPH + regular insulin</arm_group_label>
    <other_name>novolin N</other_name>
    <other_name>novolin R</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Males or females between the ages of 18 and 70 years admitted to a general medical
             service.

          2. A known history of type 2 diabetes mellitus &gt; 3 months, receiving any combination of
             oral antidiabetic agents (sulfonylureas, metformin, thiazolidinediones) and/or insulin
             therapy.

          3. Subjects must have an admission blood glucose &gt; 140 mg and &lt; 400 mg/dL and no evidence
             of ketoacidosis (serum bicarbonate &lt; 18 mEq/L, venous or arterial pH &lt; 7.30, positive
             serum or urinary ketones).

        Exclusion Criteria:

          1. Subjects with increased blood glucose concentration, but without a known history of
             diabetes.

          2. Subjects with a history of acute hyperglycemic crises such as diabetic ketoacidosis
             and hyperosmolar hyperglycemic state, or ketonuria [63].

          3. Patients with acute critical or surgical illness and/or expected to require admission
             to a critical care unit (ICU, CCU), or to undergo surgery during the hospitalization
             course.

          4. Patients with clinically relevant hepatic disease (ALT 2.5x &gt; upper limit of normal),
             or impaired renal function, as shown by a serum creatinine ≥2.0 mg/dL for males, or ≥
             1.8 mg/dL for females.

          5. History of drug or alcohol abuse within the last 2 years.

          6. Mental condition rendering the subject unable to understand the nature, scope, and
             possible consequences of the study.

          7. Patients with recognized or suspected endocrine disorders associated with increased
             insulin resistance, such as hypercortisolism, acromegaly, or hyperthyroidism.

          8. Female subjects are pregnant or breast feeding at time of enrollment into the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Baldwin, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Rush University Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Grady Memorial Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rush University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Umpierrez GE, Hor T, Smiley D, Temponi A, Umpierrez D, Ceron M, Munoz C, Newton C, Peng L, Baldwin D. Comparison of inpatient insulin regimens with detemir plus aspart versus neutral protamine hagedorn plus regular in medical patients with type 2 diabetes. J Clin Endocrinol Metab. 2009 Feb;94(2):564-9. doi: 10.1210/jc.2008-1441. Epub 2008 Nov 18.</citation>
    <PMID>19017758</PMID>
  </results_reference>
  <verification_date>May 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 27, 2007</study_first_submitted>
  <study_first_submitted_qc>January 9, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 10, 2008</study_first_posted>
  <results_first_submitted>November 12, 2013</results_first_submitted>
  <results_first_submitted_qc>June 6, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 11, 2014</results_first_posted>
  <last_update_submitted>June 6, 2014</last_update_submitted>
  <last_update_submitted_qc>June 6, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 11, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Emory University</investigator_affiliation>
    <investigator_full_name>Guillermo Umpierrez</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>type 2 diabetes</keyword>
  <keyword>inpatient hyperglycemia</keyword>
  <keyword>SQ insulin</keyword>
  <keyword>Hospitalized patients with type 2 diabetes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Isophane insulin, beef</mesh_term>
    <mesh_term>Insulin degludec, insulin aspart drug combination</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin Aspart</mesh_term>
    <mesh_term>Insulin Detemir</mesh_term>
    <mesh_term>Insulin, Isophane</mesh_term>
    <mesh_term>Isophane Insulin, Human</mesh_term>
    <mesh_term>Insulin, Long-Acting</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This study was conducted at Grady Memorial Hospital in Atlanta, GA and at Rush University Medical Center, Chicago, IL. IRB approval was given at each center and consent was obtained from all subjects. Patients with a h/o T2DM were recruited in 2007.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Detemir + Aspart</title>
          <description>Detemir insulin once daily + aspart insulin before meals</description>
        </group>
        <group group_id="P2">
          <title>NPH+Regular</title>
          <description>NPH insulin + regular insulin before breakfast and dinner</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="67"/>
                <participants group_id="P2" count="63"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="67"/>
                <participants group_id="P2" count="63"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Detemir + Aspart</title>
          <description>Detemir insulin once daily + aspart insulin before meals</description>
        </group>
        <group group_id="B2">
          <title>NPH+Regular</title>
          <description>NPH insulin + regular insulin before breakfast and dinner</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="67"/>
            <count group_id="B2" value="63"/>
            <count group_id="B3" value="130"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60"/>
                    <measurement group_id="B2" value="57"/>
                    <measurement group_id="B3" value="117"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59" spread="10"/>
                    <measurement group_id="B2" value="58" spread="10"/>
                    <measurement group_id="B3" value="58" spread="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67"/>
                    <measurement group_id="B2" value="63"/>
                    <measurement group_id="B3" value="130"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean AM BG (mg/dl)</title>
        <description>average AM daily BG with detemir insulin once daily plus insulin aspart before meals and NPH insulin twice daily plus regular insulin before meals in patients with DM2</description>
        <time_frame>during hospitalization</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Detemir + Aspart</title>
            <description>Detemir insulin once daily + aspart insulin before meals</description>
          </group>
          <group group_id="O2">
            <title>NPH+Regular</title>
            <description>NPH insulin + regular insulin before breakfast and dinner</description>
          </group>
        </group_list>
        <measure>
          <title>Mean AM BG (mg/dl)</title>
          <description>average AM daily BG with detemir insulin once daily plus insulin aspart before meals and NPH insulin twice daily plus regular insulin before meals in patients with DM2</description>
          <units>mg/dl</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
                <count group_id="O2" value="63"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="144" spread="56"/>
                    <measurement group_id="O2" value="155" spread="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Hypoglycemic Events</title>
        <description>number of patients with hypoglycemic events as defined as BG 40-59 mg/dl</description>
        <time_frame>during hospitalization</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Detemir + Aspart</title>
            <description>Detemir insulin once daily + aspart insulin before meals</description>
          </group>
          <group group_id="O2">
            <title>NPH+Regular</title>
            <description>NPH insulin + regular insulin before breakfast and dinner</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Hypoglycemic Events</title>
          <description>number of patients with hypoglycemic events as defined as BG 40-59 mg/dl</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
                <count group_id="O2" value="63"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>during study period in the hospital</time_frame>
      <desc>Hypoglycemic event is defined as blood glucose &lt; 60 mg/dl. All serious adverse events were monitored.</desc>
      <group_list>
        <group group_id="E1">
          <title>Detemir + Aspart</title>
          <description>Detemir insulin once daily + aspart insulin before meals</description>
        </group>
        <group group_id="E2">
          <title>NPH+Regular</title>
          <description>NPH insulin + regular insulin before breakfast and dinner</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoglycemia</sub_title>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="67"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Guillermo Umpierrez, MD</name_or_title>
      <organization>EUSOM</organization>
      <phone>4047781665</phone>
      <email>geumpie@emory.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

